PRQR Stock Analysis: Buy, Sell, or Hold?
PRQR - ProQR Therapeutics N.V. Ordinary Shares
$1.31
-0.14 (-9.66%)
▼
5d:
-19.63%
30d:
-30.69%
90d:
-25.57%
WAIT
LOW Confidence
Analysis Updated: Oct 16, 2026 12:00 AM ET
Earnings: Nov 05, 2026
18d
Get Alerted When PRQR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: PRQR is down 19.6% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: PRQR is down 19.6% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: PRQR is currently trading at $1.31, which is considered oversold relative to its 30-day fair value range of $1.59 to $1.89.
Technical Outlook: Technically, PRQR is in a uptrend. The price is currently testing key support at $1.30. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 9.7% recently.
Market Sentiment: PRQR scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $7.78 (+493.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PRQR is in a uptrend. The price is currently testing key support at $1.30. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 9.7% recently.
Market Sentiment: PRQR scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $7.78 (+493.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.59 -
$1.89
Company Quality Score
41/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-9.7%)
- BULLISH: Trading 493.7% below Wall St target ($7.78)
- WARNING: Composite score 41/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.59 -
$1.89
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.30
Resistance Level
$1.71
Current Trend
Uptrend
Technical data as of
Oct 16, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.83
Wall Street Target
$7.78
(+493.7%)
Revenue Growth (YoY)
120.4%
Profit Margin
-228.2%
Share & Embed Analysis
Last updated: October 17, 2026 4:20 AM ET
Data refreshes hourly during market hours. Next update: 5:20 AM
Data refreshes hourly during market hours. Next update: 5:20 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PRQR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
27 analysts |
$436 | 51 HOLD |
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
29 analysts |
$371 | 44 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
20 analysts |
$306 | 59 HOLD |
|
STOK
Stoke Therapeutics Inc |
STRONG BUY
14 analysts |
$46 | 81 BUY |
|
ORIC
Oric Pharmaceuticals Inc |
STRONG BUY
16 analysts |
$21 | 62 BUY |
